AstraZeneca PLCAZN:LSE

4,167
23.00 / 0.55 %
1.93m
5.79 %
0.542
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 03 2015 16:53 BST.

Income statement in USD

Year on year AstraZeneca PLC's net income deteriorated 51.76 % from 2.56bn to 1.23bn despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales). View full income statement

REVENUE
Gross margin78.64%
Net profit margin4.98%
Operating margin8.68%
NET INCOME
Return on assets2.27%
Return on equity6.66%
Return on investment3.21%

Growth rates in USD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by 52.14 %. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.

DIVIDEND PER SHARE
Div yield(5 year avg)0.09%
Div growth rate (5 year)4.01%
Payout ratio (TTM)276.54%
EARNINGS PER SHARE
EPS growth(5 years)-28.4085
EPS (TTM) vs
TTM 1 year ago
-38.035

Cash flow in USD

In 2014, cash reserves at AstraZeneca PLC fell by 2.83bn. However, the company earned 7.06bn from its operations for a Cash Flow Margin of 27.05%. In addition the company used 7.03bn on investing activities and also paid 2.71bn in financing cash flows. View full cash flow statement

CASH FLOW
Cash flow per share2.39
Price/Cash flow per share17.48
CASH
Book value per share8.61
Tangible book value per share-7.5109

Balance sheet in USD

AstraZeneca PLC has a Debt to Total Capital ratio of 38.40%, a higher figure than the previous year's 35.21%. View full balance sheet

TOTAL ASSETS
Current ratio0.8054
Quick ratio0.6805
TOTAL DEBT
Total debt/total equity0.6241
Total debt/total capital0.384
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.